1. UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients
   Jing Gao et al, 2013, Medical Oncology CrossRef
2. Passage of irinotecan and its active metabolite, SN-38, into human milk
   J. Nakagawa et al, 2016, Journal of Clinical Pharmacy and Therapeutics CrossRef
3. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer—Irinotecan and platinum chemotherapy
   Maki Matsumura et al, 2010, Gynecologic Oncology CrossRef
4. Multi‐institutional phase II study of neoadjuvant irinotecan and nedaplatin followed by radical hysterectomy and the adjuvant chemotherapy for locally advanced, bulky uterine cervical cancer: A Kansai Clinical Oncology Group study (KCOG‐G1201)
   Taisuke Mori et al, 2019, Journal of Obstetrics and Gynaecology Research CrossRef
5. Percutaneous interstitial brachytherapy for adrenal metastasis: technical report
   K. Kishi et al, 2012, Journal of Radiation Research CrossRef
6. Current and future potential of metallo drugs: Revisiting DNA-binding of metal containing molecules and their diverse mechanism of action
   Mehvash Zaki et al, 2016, Inorganica Chimica Acta CrossRef
7. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
   Fei-fei Han et al, 2014, Cancer Chemotherapy and Pharmacology CrossRef
8. Germline oncopharmacogenetics, a promising field in cancer therapy
   Chiara Pesenti et al, 2015, Cellular Oncology CrossRef
9. Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies
   Muneaki Shimada et al, 2012, Cancer Chemotherapy and Pharmacology CrossRef
10. miR-940 upregulation contributes to human cervical cancer progression through p27 and PTEN inhibition
    Ke Su et al, 2017, International Journal of Oncology CrossRef
11. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis
    Xue Zhang et al, 2017, Cancer Chemotherapy and Pharmacology CrossRef
12. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065)
    SATOSHI YAMAGUCHI et al, 2012, Oncology Reports CrossRef
13. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer
    Kristian Brock et al, 2021, BMC Cancer CrossRef
14. Locally advanced cervical cancer: what is the standard of care?
    Zeina Al-Mansour et al, 2010, Current Opinion in Oncology CrossRef
15. Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma
    SHIZUO MACHIDA et al, 2012, Oncology Letters CrossRef
16. Esophageal gel-shifting technique facilitating eradicative boost or reirradiation to upper mediastinal targets of recurrent nerve lymph node without damaging esophagus
    K. Kishi et al, 2013, Journal of Radiation Research CrossRef
17. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients
    Jing Gao et al, 2013, Medical Oncology CrossRef
18. Factors affecting platinum sensitivity in cervical cancer
    RINA KATO et al, 2015, Oncology Letters CrossRef
19. Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer
    Muneaki Shimada et al, 2016, International Journal of Clinical Oncology CrossRef
20. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan‐induced toxicity: A meta‐analysis
    Yuwei Yang et al, 2018, Asia-Pacific Journal of Clinical Oncology CrossRef
21. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
    Lei Cheng et al, 2014, Cancer Chemotherapy and Pharmacology CrossRef
22. Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067)
    Maki Matoda et al, 2018, Gynecologic Oncology CrossRef
23. Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis
    Xue-Qin Yang et al, 2015, BMC Cancer CrossRef